Carbetocin and Oxytocin Regimens Compared with Tranexamic Acid for Postpartum Hemorrhage Prevention

Postpartum hemorrhage (PPH) remains the leading cause of maternal morbidity and mortality globally, accounting for approximately 25% of maternal deaths worldwide. Current standard-of-care for PPH prevention after normal vaginal delivery primarily relies on uterotonic agents like oxytocin. However, the efficacy of oxytocin can be variable, and there's an ongoing need to optimize prophylactic strategies. This study investigates whether newer uterotonics like carbetocin, either alone or in combination with antifibrinolytics such as tranexamic acid, offer superior blood loss reduction compared to oxytocin-based regimens.

Investigators designed a study to compare four distinct treatment regimens for preventing postpartum blood loss originating from the uterus after normal vaginal delivery. The study involved four groups: the 1st group received carbetocin alone, the 2nd group received oxytocin alone, the 3rd group received carbetocin combined with tranexamic acid, and the 4th group received oxytocin combined with tranexamic acid. The primary aim was to reduce the mean blood loss following vaginal delivery, evaluating the comparative efficacy of these different pharmacological approaches. Specific doses, routes, or durations were not detailed in the abstract.